Korean Journal of Nephrology 1993;12(1):62-67.
만성 신부전 환자에서 Recombinant Human Erythropoietin ( rHuEPO ) 투여에 따른 심장의 기능 및 형태학적 변화
박원도 , 송일환 , 강흥선 , 안재형 , 이태원 , 임천규 , 배종화 , 김명재
Abstract
Background
Hemodynamic changes often occur in patients with chronic renal failure. Hyperdynamic state is probably contributory determinent of the congestive uremic cardiomyopathy in these patients. Renal anemia is the most important factor in these changes. Methods: Using echocardiography, we evaluated the hemodynamic changes in thirteen patients with severe renal anemia (Hct<23%) before and after treatment with recombinant human erythropoietin (rHuEPO). Thirteen patients on maintenance hemodialysiswere treated with rHuEPO 50IU/kg intravenously three times per week for twelve weeks. Results: Under rHuEPO treatment, hematocrit rose from 19.8±1.8% to 30.4±2.5% (p<0.01) and blood pres- sure significantly increased (p<0.05). Left vetricular dimension and volume were decreased but not signifi- cantly. Cardiac wall thickness was unchanged during study period. Posttreatment cardiac index was de- creased (5.5±1.6 vs 4.3±1.3 liter/min/m) when compar- ed with pretreatment period (p<0.05). Concluaion: This study suggested that partial correc- tion of renal anemia by rHuEPO therapy results in improvement of hemodynamic impairment in patients with congestive uremic cardiomyopathy. The decrease of cardiac index might well be a result of improved cardiac funtion and peripheral vasoconstriction due to increased oxygen availability.
TOOLS
METRICS Graph View
  • 343 View
  • 10 Download
Related articles


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736    Fax: +82-2-3486-8737    E-mail: registry@ksn.or.kr                

Copyright © 2024 by The Korean Society of Nephrology.

Developed in M2PI

Close layer